IP Library Granted Patent US 10,889,538
Granted Patent B2
US 10,889,538 · App. 16/306,524 · Granted Jan 12, 2021

Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same

Inventors: Eric Verdin (Mill Valley, CA); Scott Michael Ulrich (Brooktondale, NY); John C. Newman (San Francisco, CA)
Assignees: The J. David Gladstone Institutes; The Regents of The University Of California; Ithaca College
C07C69/34A23L33/12A61K31/23A61P9/10A61P13/12A61P25/08A61P25/16A61P25/28A61P35/00G02B1/04A23V2002/00A23V2200/322A23V2250/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,889,538
App. No.
16/306,524
Granted
Jan 12, 2021
Kind
B2
Abstract

Aspects of the present disclosure include fatty acid β-hydroxyester compounds (e.g., fatty acid esters of β-hydroxybutyrate), fatty acid esters of butanediol, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions having one or more fatty acid β-hydroxyester compounds and/or one or more fatty acid esters of butanediol. Methods for treating a subject by administering one or more esters to the subject are also provided. Kits containing one or more of the subject esters are also described.

Claims (31)

1. A method of reducing epileptiform activity in the brain of a subject and/or treating in said subject one or more conditions selected from the group consisting of Alzheimer's disease, epilepsy, Parkinson's disease, heart failure, traumatic brain injury, stroke, hemorrhagic shock, acute lung injury after fluid resuscitation, acute kidney injury, myocardial infarction, myocardial ischemia, diabetes, glioblastoma multiforme, diabetic neuropathy, prostate cancer, amyotrophic lateral sclerosis, Huntington's disease, cutaneous T cell lymphoma, multiple myeloma, peripheral T cell lymphoma, HIV, and Niemann-Pick Type C disease said method comprising:

administering to said subject, a therapeutically effective amount of a compound of Formula I:

wherein:

R 1 is H or C(1-6) alkyl or substituted alkyl; and

R 2 and R 3 are independently unsubstituted or substituted C(4-30) alkyl.

2. The method according to claim 1 , wherein the therapeutically effective amount is sufficient to reduce epileptiform activity in the brain of the subject.

3. The method of claim 2 , wherein said method comprises a method of reducing epileptiform activity in the brain of a subject.

4. The method of claim 1 , wherein R 1 is an unsubstituted C(1-6) alkyl.

5. The method of claim 4 , wherein R 1 is methyl.

6. The method of claim 1 , wherein, wherein R 2 and R 3 are independently unsubstituted C(6-18) alkyl.

7. The method of claim 6 , wherein R 2 and R 3 are independently unsubstituted C6 alkyl.

8. The method of claim 6 , wherein R 2 and R 3 are independently unsubstituted C8 alkyl.

9. The method of claim 1 , wherein the compound is of Formula Ia:

10. The method of claim 1 , wherein said compound has the formula Ib:

11. The method of claim 9 , wherein said compound has the formula:

12. The method of claim 9 , wherein said compound has the formula:

13. The method of claim 1 , wherein said compound is provided in an ingestible composition.

14. The method of claim 13 , wherein said composition comprises a food supplemented with one or more of said compound.

15. The method of claim 13 , wherein the compound is present in the composition in an amount of from about 1% w/w to about 25% w/w.

16. The method of claim 14 , wherein said food comprises one or more additional components of a ketogenic diet.

17. The method of claim 16 , wherein the ketogenic diet comprises a ratio by mass of fat to protein and carbohydrates of from about 2:1 to about 10:1.

18. The method of claim 13 , wherein said one or more compounds comprises a compound having the formula:

19. The method of claim 13 , wherein said one or more compounds comprises a compound having the formula:

20. The method of claim 1 , wherein said compound is provided in an oral preparation comprising said compound and a preservative and/or a flavoring agent.

21. The method of claim 20 , wherein said preparation comprises a syrup or an elixir.

22. The method of claim 20 , wherein said preparation comprises a suspension.

23. The method of claim 20 , wherein said preparation comprises a binder.

24. The method of claim 23 , wherein said preparation comprises a binder selected from the group consisting of cellulose, methylcellulose, hydroxymethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, poly(ethylene glycol), sucrose, and starch.

25. The method of claim 20 , wherein said preparation comprises a flavoring agent.

26. The method of claim 20 , wherein said preparation comprises a preservative.

27. The method of claim 26 , wherein said preparation comprises a preservative selected from the group consisting of sodium benzoate, sodium bisulfite, methylparaben, and propylparaben.

Assignments (4)
CONFIRMATORY LICENSE Recorded Aug 17, 2021
From: J. DAVID GLADSTONE INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 057208/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2020
From: VERDIN, ERIC
To: THE J. DAVID GLADSTONE INSTITUTES
Reel/Frame 052289/0566 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2020
From: ULRICH, SCOTT MICHAEL
To: ITHACA COLLEGE
Reel/Frame 052289/0570 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2020
From: NEWMAN, JOHN C.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 052289/0627 →
Continuity (2)
Provisional Application 62346975 · Jun 7, 2016
Related Publication 20190248730A1 · Aug 15, 2019